[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "MMR vaccine and COVID immunity", "description": "Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients\n\nhttps://mbio.asm.org/content/11/6/e02628-20\n\nThe measles-mumps-rubella (MMR) vaccine\n\nTheorized to provide protection against coronavirus disease\n\nTo determine whether any MMR IgG titers are inversely correlated with covid severity\n\nComparing MMR titers to recent COVID-19 severity levels.\n\nThe MMR II group\n\n50 subjects who would primarily have MMR antibodies from the MMR II vaccine\n\nComparison group\n\n30 subjects consisted of those who would primarily have MMR antibodies from sources other than MMR II\n\nIncluding prior measles, mumps, and/or rubella illnesses\n\nResults in the MMR group\n\nSignificant inverse correlation (rs\u2009=\u2009\u22120.71, P\u2009less than\u20090.001) \n\nBetween mumps virus titers and COVID-19 severity\n\nResults in the comparison group\n\nThere were no significant correlations between mumps IgG titers and severity in the comparison group\n\nResults in both groups\n\nNo correlation between between severity and measles or rubella titers in either group\n\nScale of the observation\n\nMumps titers of 134 to 300\u2009arbitrary units (AU)/ml (n\u2009=\u20098), functionally immune or asymptomatic\n\nLess than 134, (n=17) all had mild symptoms\n\nLess than 75, (n=11) all had moderate symptoms\n\nLess than 32, all who had been hospitalized and had required oxygen\n\nOur results demonstrate that there is a significant inverse correlation between mumps titers from MMR II and COVID-19 severity\n\nFour important points\n\nYoung children are largely spared from severe disease\n\nSecond, numerous countries have COVID-19 death rates that are as low as 1% of the death rates of other countries\n\nMany people, despite prolonged close contact with someone who is COVID-19 positive, never test positive themselves\n\nNearly half of people who test positive for COVID-19 are asymptomatic\n\nMechanism of action\n\nSequence homology between both mumps and measles and rubella with SARS-CoV-2\n\nAfter two doses\n\n97% protected against measles\n\n88% against mumps\n\n97% against rubella\n\nNHS site\n\nhttps://www.nhs.uk/conditions/vaccinations/mmr-vaccine/\n\nBorn between 1970 and 1979, as you may have only been vaccinated against measles\n\nBorn between 1980 and 1990, as you may not be protected against mumps\nBradford Hill\nStrength of association\nConsistency\nReproducibility\nSpecificity\nTemporality\nBiological gradient, dose response\nPlausibility\nCoherence with lab findings\nExperiment\nReversibility", "link": "https://www.youtube.com/watch?v=zdAPgglDJAU", "date_published": "2020-11-22 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Vaccinations in December", "description": "Light at the end of the tunnel. Cavalry coming over the hill. End of the beginning and the beginning of the end. In other words, things are looking better for next year.", "link": "https://www.youtube.com/watch?v=T5QkrSfI0lI", "date_published": "2020-11-21 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Weekend Update", "description": "US excess deaths\n\nCurrently above average in 50 States\n\nhttps://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm#dashboard\n\nMarch 15 to November 7\n\nDeaths nationwide, 18 % percent higher than normal\n\nDeaths above normal, 326,000\n\nCovid deaths, 251,715\n\nUS trends\n\nhttps://covid.cdc.gov/covid-data-tracker/#trends_dailytrendscases\n\nDonald Trump, Jr., (42) tested positive on Friday, has entered quarantine\n\nCanadian\n\nToronto prepares 28 day lockdown Monday\n\nA normal Christmas is quite frankly right out of the question\n\nMexico\n\nOver 1 million confirmed cases\n\nTest confirmed deaths, 100,000\n\nUK\n\nhttps://coronavirus.data.gov.uk/details/cases\n\nhttps://covid.joinzoe.com/data#interactive-map\n\nONS\n\nhttps://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveypilot/20november2020\n\n8 November to 14 November 2020\n\nEngland\n\nPrevalence, 664,700 infections\n\nOne in 80 people\n\n38,900 new cases per day\n\nRates increasing\n\nLondon, East of England South East\n\nRates decreasing \n\nNorth West, East Midlands\n\nHighest positivity rates\n\nSecondary school-aged, older teenagers, young adults\n\nWales\n\nPositivity rates peaked end of October\n\nOne in 165\n\nNorthern Ireland\n\nRates decreasing over past four weeks\n\nOne in 135 \n\nScotland\n\nRates levelled of\n\nOne in 155\n\nWHO and remdesivir (20th November)\n\nhttps://www.who.int/news-room/feature-stories/detail/who-recommends-against-the-use-of-remdesivir-in-covid-19-patients\n\nhttps://www.dw.com/en/coronavirus-who-advises-against-remdesivir-for-hospitalized-covid-19-patients/a-55671134?maca=en-NL-Corona-Compact\n\nhttps://bnf.nice.org.uk/drug/remdesivir.html\n\nConditional recommendation against the use of remdesivir in hospitalized patients\n\nRegardless of disease severity\n\nCurrently no evidence that remdesivir improves survival and other outcomes\n\nGuideline, developed by international guideline development group\n\n28 clinical care experts, 4 patient-partners, one ethicist\n\nMatch scientific standards with the speed required to respond to an ongoing pandemic\n\nWHO Solidarity Trial, 3 other randomized controlled trials\n\nN = 7000\n\nInsufficient evidence of an important effect on: \n\nMortality\n\nNeed for mechanical ventilation\n\nTime to clinical improvement\n\nOther patient-important outcomes\n\nSupported continued enrollment in trials evaluating remdesivir.\n\nA conditional recommendation\n\nWhen the evidence around the benefits and risks of an intervention are less certain\n\nIn this case, there is a conditional recommendation against the use of remdesivir\n\nThis means that there isn\u2019t enough evidence to support its use.\n\nUS pharmaceutical company Gilead\n\nDisputes the findings\n\nWHO's findings were yet to be subjected to peer review\n\nRemdesivir is currently approved for use as a COVID-19 in over 50 countries\n\nCost\n\nhttps://www.bmj.com/content/371/bmj.m4457\n\nA treatment cycle may take 5-10 days\n\nA five day course of treatment for one patient costs around $2340 (\u00a31773; \u20ac1976) for government programmes\n\n$3120 for private insurers\n\nGilead has reached agreements to make cheaper generic versions available in low and middle income countries\n\n(Tamiflu costs less than $75 per course of treatment to shorten symptom duration for patients with influenza)", "link": "https://www.youtube.com/watch?v=SWFFREep6tQ", "date_published": "2020-11-21 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]